Optipharm옵티팜
153710 · KOSDAQ · ₩153710 · 옵티팜
₩4,375▲ ₩25 (0.57%)End-of-day · Oct 28, 2026 · End-of-day prices.
Filings
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Sep 18, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Aug 12, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 29, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 29, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최May 20, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 23, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 23, 2026Open on DART
- Audit report submitted감사보고서제출Mar 13, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 13, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 6, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 6, 2026Open on DART
- [Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고Feb 6, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jan 27, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Nov 14, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 23, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 1, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Sep 3, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jul 31, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 30, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Jun 10, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서May 19, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 선정)May 2, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 11, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 24, 2025Open on DART
- [Corrected] New Facility Investment, etc.[기재정정]신규시설투자등Mar 20, 2025Open on DART
- Audit report submitted감사보고서제출Mar 14, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 14, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Mar 7, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 7, 2025Open on DART
- [Amended] Notice of Stock Purchase Option Grant[기재정정]주식매수선택권부여에관한신고Dec 31, 2024Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 10, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Nov 20, 2024Open on DART
- Quarterly report (Sep 2024)분기보고서 (2024.09)Nov 14, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Nov 4, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Sep 25, 2024Open on DART
- New Facility Investment, etc.신규시설투자등Sep 2, 2024Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Aug 20, 2024Open on DART
- Half-year report (Jun 2024)반기보고서 (2024.06)Aug 14, 2024Open on DART
- Quarterly report (Mar 2024)분기보고서 (2024.03)May 16, 2024Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (민군겸용 기술개발사업(형질전환돼지 기반 수혈가능 이종적혈구제제 기술개발) 국책과제 선정)May 2, 2024Open on DART
- Annual general meeting results정기주주총회결과Mar 25, 2024Open on DART
- Notice on Grant of Stock Purchase Options주식매수선택권부여에관한신고Mar 25, 2024Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 25, 2024Open on DART
Titles in Korean until English translations are added.
Also known as: Optipharm / 옵티팜 / 153710 / KRX:153710
Source: KRX statistical information